Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Equity Ratio (2021 - 2025)

Historic Equity Ratio for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to 0.92.

  • Amylyx Pharmaceuticals' Equity Ratio rose 1695.19% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 1695.19%. This contributed to the annual value of 0.85 for FY2024, which is 158.61% up from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Equity Ratio stood at 0.92 for Q3 2025, which was up 1695.19% from 0.86 recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Equity Ratio peaked at 0.92 during Q1 2025, and registered a low of 1.43 during Q4 2021.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Equity Ratio value was 0.85 (recorded in 2022), while the average stood at 0.71.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Equity Ratio surged by 16079.05% in 2022 and then tumbled by 1272.96% in 2024.
  • Amylyx Pharmaceuticals' Equity Ratio (Quarter) stood at 1.43 in 2021, then skyrocketed by 160.79% to 0.87 in 2022, then fell by 3.73% to 0.84 in 2023, then rose by 1.59% to 0.85 in 2024, then rose by 7.56% to 0.92 in 2025.
  • Its Equity Ratio stands at 0.92 for Q3 2025, versus 0.86 for Q2 2025 and 0.92 for Q1 2025.